Immix Biopharma, Inc. IMMX Prepaid Research And Development Expenses
Prepaid Research And Development Expenses at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept IMMX:PrepaidResearchAndDevelopmentExpenses.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s prepaid research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s prepaid research and development expenses?
- Immix Biopharma, Inc. (IMMX) reported prepaid research and development expenses of $1.23M in Q1 2026.
- How has Immix Biopharma, Inc.'s prepaid research and development expenses changed year-over-year?
- Immix Biopharma, Inc.'s prepaid research and development expenses increased by 228.9% year-over-year, from $372.92K to $1.23M.
- What is the long-term trend for Immix Biopharma, Inc.'s prepaid research and development expenses?
- Over 3 years (2022 to 2025), Immix Biopharma, Inc.'s prepaid research and development expenses has grown at a -14.4% compound annual growth rate (CAGR), from $792.13K to $497.71K.
- What does prepaid research and development expenses mean?
- This represents payments made in advance for research and development services, such as clinical trial site fees or contract research organization (CRO) services, that have not yet been performed. It reflects the company's commitment to future clinical activities and the timing of its R&D cash outflows. Tracking this helps in understanding the pipeline's operational momentum.